Rebecca M. Minter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rebecca M. Minter has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Michael A. Choti
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA
6 shared publications- Ibrahim Nassour
Department of Surgery, University of Florida College of Medicine, Gainesville, FL 32608
5 shared publications - Sam C. Wang
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA
5 shared publications - Adam C. Yopp
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, USA
4 shared publications - John C. Mansour
Department of Surgery, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center (UTSW), Dallas, Texas
4 shared publications - Patricio M. Polanco
Department of Surgery, Surgical Oncology, The University of Texas Southwestern Medical Center, Dallas, USA
4 shared publications
Latest Publications
- Open Access
- 1 November 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 21 (11) , 1784-1792
Robotic Versus Laparoscopic Pancreaticoduodenectomy: a NSQIP Analysis
- 1 November 2017
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 21 (11) , 1784-1792
Open AccessRobotic Versus Laparoscopic Pancreaticoduodenectomy: a NSQIP Analysis
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , e125-e126
Predictors and Outcomes of Minimally Invasive Distal Pancreatectomy Conversion
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , e125-e126
Predictors and Outcomes of Minimally Invasive Distal Pancreatectomy Conversion
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S132
Conversion of Minimally Invasive Pancreaticoduodenectomy: Predictors and Outcomes
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S132
Conversion of Minimally Invasive Pancreaticoduodenectomy: Predictors and Outcomes
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S129
Adjuvant Therapy Is Associated with Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study
- 1 October 2017
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 225 (4) , S129
Adjuvant Therapy Is Associated with Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 717
Effect of adjuvant chemotherapy following pathologic complete response on long-term survival in rectal cancer: A propensity score matched analysis.
717 Background: The role of adjuvant chemotherapy following resection in patients with rectal cancer that achieve pathologic complete response (pCR) after neoadjuvant therapy is unclear. Current data have been limited by small sample size series. This study examined the impact of adjuvant chemotherapy following pCR on overall survival in a national cohort of patients. Methods: Patients with rectal adenocarcinoma were identified in the National Cancer Data Base between 2006 and 2012. Those with locally advanced tumor (clinical stage II or III) that achieved pCR (defined as ypT0N0 in surgical specimens) after neoadjuvant chemoradiotherapy (nCRT) were included in the study. We matched by propensity score patients that received adjuvant chemotherapy (ACT) and patients that did not receive postoperative treatment (no-ACT) controlling for demographic as well as perioperative patient and tumor characteristics. Overall survival was compared using a Cox proportional hazards model. Results: We identified 2,543 patients (ACT: 732, no-ACT: 1,811 patients) with resected locally advanced rectal adenocarcinoma that achieved pCR after nCRT. Among patients that received ACT, 711 were matched with 711 patients in the no-ACT group. Adjuvant chemotherapy was associated with improved overall survival compared to no-ACT (hazard ratio[HR] = 0.46, 95% confidence interval [CI] = 0.29 – 0.75). Overall survivals at 1, 3, and 5 years in the ACT and no-ACT groups were 100% vs 98% (P=0.1), 98% vs 94% (P
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 717
Effect of adjuvant chemotherapy following pathologic complete response on long-term survival in rectal cancer: A propensity score matched analysis.
717 Background: The role of adjuvant chemotherapy following resection in patients with rectal cancer that achieve pathologic complete response (pCR) after neoadjuvant therapy is unclear. Current data have been limited by small sample size series. This study examined the impact of adjuvant chemotherapy following pCR on overall survival in a national cohort of patients. Methods: Patients with rectal adenocarcinoma were identified in the National Cancer Data Base between 2006 and 2012. Those with locally advanced tumor (clinical stage II or III) that achieved pCR (defined as ypT0N0 in surgical specimens) after neoadjuvant chemoradiotherapy (nCRT) were included in the study. We matched by propensity score patients that received adjuvant chemotherapy (ACT) and patients that did not receive postoperative treatment (no-ACT) controlling for demographic as well as perioperative patient and tumor characteristics. Overall survival was compared using a Cox proportional hazards model. Results: We identified 2,543 patients (ACT: 732, no-ACT: 1,811 patients) with resected locally advanced rectal adenocarcinoma that achieved pCR after nCRT. Among patients that received ACT, 711 were matched with 711 patients in the no-ACT group. Adjuvant chemotherapy was associated with improved overall survival compared to no-ACT (hazard ratio[HR] = 0.46, 95% confidence interval [CI] = 0.29 – 0.75). Overall survivals at 1, 3, and 5 years in the ACT and no-ACT groups were 100% vs 98% (P=0.1), 98% vs 94% (P
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 25
Racial and ethnic disparities among young patients with gastric cancer.
25 Background: Although up to 15% of patients with gastric cancer present at young age, the characteristics of these patients are not well described. We sought to determine if there are different clinical and pathologic characteristics associated with race and ethnicity in young gastric cancer patients. Methods: We identified all gastric adenocarcinoma patients who were younger than 45 years in the National Cancer Data Base between 2006 and 2013. We analyzed patient, tumor, and treatment-related factors as well as overall survival using standard statistical methods. Results: 5,869 patients were identified with 40.6% being Non-Hispanic Whites (NHW), 27.7% Hispanics (HS), 16.9% African Americans (AA), and 9.0% Asians (AS). HS patients presented at a younger age compared to the other groups (p < 0.01). HS presented most often with metastatic disease (59.2%) followed by AA (50.2%), NHW (49.6%), and AS (49.8%; p < 0.01). NHW presented more often with tumors in the cardia (45.7%) compared to AA (12.7%), HS (12.5%), and AS (9.6%, p < 0.01). HS (28.4%) and AA (14.2%) were more likely to be uninsured compared to AS (12.0%) and NHW (7.1%; p < 0.01). AA (60.5%) and HS (49.1%) were more likely to have below median income compared to NHW (35.8%) and AS (24.2%, p < 0.01). AS had better overall outcome, with median overall survival of 22.7 months compared to 15.2 months for NHW, 14.0 months for HS and 13.6 months for AA (p < 0.01). Independent variables associated with favorable survival included being AS or HS, cardia tumor, treatment at an academic center, higher income, and low Charlson Comorbidity Index. Conclusions: There is racial/ethnic variability in disease presentation, treatment delivery, and outcomes in young gastric cancer patients. Further studies are warranted to determine whether these variations are due to disparity in health care access and/or inherent difference in biology.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (4_suppl) , 25
Racial and ethnic disparities among young patients with gastric cancer.
25 Background: Although up to 15% of patients with gastric cancer present at young age, the characteristics of these patients are not well described. We sought to determine if there are different clinical and pathologic characteristics associated with race and ethnicity in young gastric cancer patients. Methods: We identified all gastric adenocarcinoma patients who were younger than 45 years in the National Cancer Data Base between 2006 and 2013. We analyzed patient, tumor, and treatment-related factors as well as overall survival using standard statistical methods. Results: 5,869 patients were identified with 40.6% being Non-Hispanic Whites (NHW), 27.7% Hispanics (HS), 16.9% African Americans (AA), and 9.0% Asians (AS). HS patients presented at a younger age compared to the other groups (p < 0.01). HS presented most often with metastatic disease (59.2%) followed by AA (50.2%), NHW (49.6%), and AS (49.8%; p < 0.01). NHW presented more often with tumors in the cardia (45.7%) compared to AA (12.7%), HS (12.5%), and AS (9.6%, p < 0.01). HS (28.4%) and AA (14.2%) were more likely to be uninsured compared to AS (12.0%) and NHW (7.1%; p < 0.01). AA (60.5%) and HS (49.1%) were more likely to have below median income compared to NHW (35.8%) and AS (24.2%, p < 0.01). AS had better overall outcome, with median overall survival of 22.7 months compared to 15.2 months for NHW, 14.0 months for HS and 13.6 months for AA (p < 0.01). Independent variables associated with favorable survival included being AS or HS, cardia tumor, treatment at an academic center, higher income, and low Charlson Comorbidity Index. Conclusions: There is racial/ethnic variability in disease presentation, treatment delivery, and outcomes in young gastric cancer patients. Further studies are warranted to determine whether these variations are due to disparity in health care access and/or inherent difference in biology.
- 1 February 2016
- Published by Elsevier in Surgical Clinics of North America
- Vol. 96 (1) , 1-13
Medical School Training for the Surgeon
- 1 February 2016
- Published by Elsevier in Surgical Clinics of North America
- Vol. 96 (1) , 1-13
Medical School Training for the Surgeon